Category: Market News

Oxford Nanopore Technologies (LSE:ONT) has reported a strong trading performance for 2025, with full-year revenue expected to reach approximately £223–224 million. This represents growth of around 22% on a reported basis and 24% at constant currency, modestly ahead of the company’s prior guidance.

Revenue growth was broad-based across both regions and end markets. All major geographic areas delivered constant-currency growth of more than 20%. By end market, Clinical revenue led performance with growth of around 60%, followed by BioPharma at roughly 30% and Applied Industrial at about 27%. Research revenue increased by approximately 15%, despite ongoing funding pressures in that segment. Product demand was particularly strong for the PromethION platform range, which recorded year-on-year growth of more than 40%, highlighting continued uptake of the company’s high-throughput sequencing systems.

Oxford Nanopore also noted continued progress toward profitability and closed 2025 with around £302 million in cash and liquid investments, exceeding market expectations and providing a robust financial base to support its long-term strategy. The company is scheduled to release its preliminary results for the year ended 31 December 2025 on 2 March 2026, alongside a management presentation and question-and-answer session.

From an investment perspective, the outlook reflects a balance between encouraging operational momentum and ongoing financial and technical challenges. While revenue growth and a strategic emphasis on improving profitability are positive signals, broader market conditions and current financial metrics continue to present meaningful risks.

More about Oxford Nanopore Technologies PLC

Oxford Nanopore Technologies PLC is a life sciences and biotechnology company that has developed nanopore-based sensing technology enabling real-time, high-performance analysis of DNA and RNA. Its sequencing platforms are deployed in more than 125 countries across research, clinical, biopharma, applied industrial and pathogen surveillance applications, with potential uses spanning healthcare, food and agriculture.

Plus500 (LSE:PLUS) has reported full-year 2025 revenue of approximately $792m and EBITDA of around $348m, both exceeding market expectations. EBITDA rose by roughly 8% on a constant-currency basis compared with 2024, while cash balances stood at about $0.8bn at year end, despite the distribution of roughly $380m to shareholders over the period.

The group highlighted continued progress in shifting its client base toward longer-term, higher-value customers. Customer acquisition costs declined by more than 10%, and around half of OTC revenue is now generated by clients who have been trading on the platform for more than five years. Active customer numbers were broadly stable, reflecting a focus on quality rather than volume.

Strategically, Plus500 strengthened its position in the U.S. futures market through two significant B2B partnerships. These included acting as clearing partner for CME Group’s new prediction market platform launched in collaboration with FanDuel, and becoming the exclusive clearing and technology provider for Topstep Brokerage. Together, these agreements underline Plus500’s evolution into a scaled market infrastructure provider. The company also expanded its OTC operations with new regulatory licences in the UAE and Canada, and established its first presence in Latin America through a representative office in Colombia. Management highlighted the scarcity and breadth of its global licensing footprint as a key competitive advantage and a marker of regulatory credibility.

Capital allocation remained firmly shareholder-focused, with total returns of $365m in 2025, including $200m of share buybacks. This performance has left Plus500 as the best-performing stock in the FTSE All-Share on a total return basis since its IPO in 2013, reinforcing confidence in continued financial strength and strategic momentum into 2026.

Overall, Plus500 continues to demonstrate strong financial delivery and supportive technical indicators, underpinned by disciplined capital returns and strategically important partnerships. A relatively low valuation multiple and attractive dividend yield add to the investment case, although the absence of recent earnings call commentary limits visibility on management’s longer-term outlook.

More about Plus500

Plus500 is a global multi-asset fintech group operating proprietary, technology-driven trading platforms. The company offers contracts for difference (CFDs), share dealing, and futures and options on futures. It is highly regulated, holding 16 operating licences across major jurisdictions including the UK, U.S., Europe, Asia-Pacific, the Middle East and Latin America, and provides access to more than 2,500 underlying financial instruments for retail customers in over 60 countries via web and mobile platforms.

Bow Street Group (LSE:BOW) has reported signs of stabilisation in trading for the year ended 28 December 2025, with like-for-like revenue increasing by more than 1.3% during the key four-week Christmas trading period. The company said full-year results are expected to be in line with market expectations.

After completing a £10.1m equity raise, implementing a company name change and refreshing its leadership team, the group has initiated a wide-ranging operational reset. This includes the rollout of more than 280 improvement initiatives across the business, the exit of a marginally profitable Gerrards Cross lease on favourable cash terms, and the introduction of new employee and share option incentive schemes. Bow Street has also begun refurbishing an initial six restaurants and rolling out updated menus, aimed at mitigating the impact of rising wage and business rate costs expected from April 2026. Early trading performance at refurbished locations has been described as encouraging.

In addition, the group confirmed it is in constructive discussions regarding the potential acquisition of scalable restaurant brands. Together, these actions position 2026 as a year focused on rebuilding and transformation for the business.

From an investment standpoint, the outlook remains cautious due to ongoing financial and technical pressures. High leverage and negative equity continue to pose risks to balance sheet stability, while technical indicators point to a bearish trend despite oversold conditions. Valuation metrics remain unattractive, reflecting continuing losses and the absence of dividend support.

More about Bow Street Group

Bow Street Group plc, listed on AIM, owns and operates the Wildwood and dim t casual dining restaurant brands in the UK. The group manages a mixed portfolio of long and short leasehold sites, offering European and Asian cuisine, and is pursuing a strategy centred on operational improvement and selective acquisitions within the UK restaurant sector.

CelLBxHealth plc (LSE:CLBX) has announced a series of board changes, including the immediate appointment of Peter Collins as chief executive officer. The company has also strengthened its non-executive leadership with the appointments of Klaas de Boer, Kim Oreskovic and Benjamin Hart as non-executive directors, while current non-executive director Joseph Eid is set to step down at the end of January 2026.

Executive chair Jan Groen said the expanded board brings additional life sciences, commercial and strategic expertise at a pivotal point for the business. The leadership refresh is intended to support the pursuit of new strategic opportunities and enhance long-term shareholder value, as CelLBxHealth continues the commercial rollout of its Parsortix circulating tumour cell (CTC) platform and related services.

From a market perspective, the company’s outlook remains constrained by significant financial pressures and bearish technical indicators, which represent the most influential factors for sentiment. Although recent corporate developments and progress highlighted in earnings communications provide some support, concerns around financial performance and valuation continue to weigh heavily on the overall outlook.

More about CelLBxHealth plc

CelLBxHealth plc, listed on AIM under the ticker CLBX, is a circulating tumour cell intelligence company delivering CTC-based solutions for research, drug development and clinical oncology. Its patented Parsortix platform isolates circulating tumour cells from blood samples and integrates with existing laboratory systems, enabling downstream applications such as whole-cell imaging, proteomic profiling and genomic analysis. The company generates revenue through sales of the Parsortix system and consumables, provision of laboratory services for clinical trials and assay development, and lab-developed tests supported by strategic partnerships, with services delivered from its GCLP-certified laboratory in the UK.

EARNZ plc (LSE:EARN) has reported that its first full-year results for the period to 31 December 2025 are in line with market expectations, marking a solid performance around 18 months after the company’s formation in 2024 and the rollout of its buy-and-build strategy. Over the period, the group successfully integrated its 2024 acquisitions of Cosgrove & Drew and South West Heating Services, both of which exceeded consolidated forecasts during 2025.

The 2025 acquisition of A&D Carbon Solutions has also contributed positively, supporting delivery of a major retrofit and renewables contract in Bradford while extending the group’s footprint into commercial solar projects. In parallel, EARNZ launched National Retrofit Solutions to target insurance-led insulation work, alongside Warm Low Living, which is focused on regional public-sector retrofit programmes. More recently, the group has secured additional public-sector contract awards in Dorset and Leeds, which management expects to support sustainable, long-term growth, despite the significant capital investment made into acquisitions and new subsidiaries since listing in August 2024.

From an investment perspective, the company’s outlook remains weighed down by weak financial performance and challenging valuation metrics, reflecting ongoing pressure on profitability and cash flow management. Technical indicators also point to bearish sentiment. While recent corporate progress and contract wins provide some encouragement, they are currently insufficient to fully counterbalance the underlying financial and technical headwinds.

More about EARNZ plc

EARNZ plc is a UK-listed group operating in the energy efficiency and retrofit market. The company provides insulation and ventilation upgrades, renewable energy solutions and commercial solar installations, serving residential and non-residential property portfolios across public sector, private sector and insurance-backed markets.

Haydale Graphene Industries (LSE:HAYD) has completed the acquisition of Intelligent Resource Management, which trades as SaveMoneyCutCarbon (SMCC), in a transaction it describes as a major step in its evolution from a graphene materials developer into a scalable clean-technology platform. The deal was supported by a £5.75m fundraising, attracting backing from strategic investors, senior management and strong retail participation.

The acquisition provides Haydale with a national, partner-funded customer acquisition model through SMCC’s established relationships with major UK banks and utilities. It also adds a fully integrated B2B delivery platform for energy- and water-efficiency projects. Haydale plans to integrate its graphene-based JustHeat heating system, along with future graphene-enhanced products, into SMCC’s Sustainability Hub and Impact Partner Programme. This is expected to significantly broaden the group’s route to market and could accelerate revenue generation.

As part of the transaction, SMCC co-founder Mark Sait has joined the Haydale board as Chief Commercial Officer. The enlarged group is positioning itself as a vertically integrated provider of practical decarbonisation solutions for the built environment. Haydale has also indicated that it intends to rebrand as Haydale plc and will provide a further update on commercial progress and integration when it reports extended-period results in early February 2026.

From a market perspective, Haydale’s outlook continues to be shaped by financial challenges, with ongoing net losses and cash flow pressures outweighing recent positive corporate developments and improving technical momentum. While the strategic rationale of the acquisition and new partnerships offers longer-term growth potential, near-term financial stability remains a key issue for investors.

More about Haydale Graphene

Haydale Graphene Industries is an advanced materials and clean-technology company focused on the development and commercial deployment of graphene-enabled solutions that improve energy and water efficiency. Its product portfolio includes commercially ready technologies across heating, cooling and energy efficiency applications. Following the acquisition of SaveMoneyCutCarbon, the group is building a vertically integrated clean-tech platform that combines proprietary graphene-based technologies with established, UK-wide market access and project delivery capabilities to support decarbonisation across residential, commercial and institutional buildings.

HyProMag USA, an associated company of Mkango Resources (LSE:MKA), has completed expansion concept studies and begun pre-feasibility work on new rare earth magnet recycling and manufacturing hubs in South Carolina and Nevada. These proposed sites would complement the company’s initial facility in Texas, forming a modular, three-hub U.S. platform.

Under the current plan, the expanded network would lift U.S. neodymium iron boron (NdFeB) magnet and alloy capacity to 4,656 metric tons per year by 2029, effectively tripling output. The development underpins a projected post-tax net present value of more than $2 billion, alongside strong anticipated returns. The strategy is also designed to support a potential future U.S. listing, reinforce domestic supply chains for critical technologies such as artificial intelligence and electric vehicles, and create approximately 300 skilled manufacturing jobs. In parallel, the expansion would further strengthen HyProMag’s positioning in low-carbon, recycled magnet production.

More about Mkango Resources

Mkango Resources, listed on AIM and TSX-V, is positioning itself as a leading player in recycled rare earth magnets, alloys and oxides through its majority ownership of Maginito and its indirect interest in HyProMag. Through HyProMag USA, the group is focused on building a secure, low-carbon U.S. supply chain for neodymium iron boron magnets used across AI infrastructure, defence, robotics, electric vehicles and advanced electronics. This strategy is underpinned by proprietary hydrogen processing of magnet scrap (HPMS) recycling technology developed with significant research and development support from the University of Birmingham.

Renalytix (LSE:RENX) has announced further expansion of the U.S. clinical reach of its kidneyintelX.dkd test, following the completion of three new electronic health record–integrated deployments with regional kidney care providers in New York, Florida and Tennessee. Testing is now underway across these sites, with the rollout designed around streamlined, one-click ordering to support a gradual increase in utilisation.

The company is continuing with a disciplined and resource-efficient commercial strategy, while also strengthening its collaboration with Tempus AI. This partnership is focused on embedding kidneyintelX.dkd within the electronic records and data infrastructure of major health systems, laying the groundwork for broader geographic penetration and expanded clinical adoption over time. Alongside these operational developments, Renalytix has been increasing investor engagement, including participation at the J.P. Morgan Healthcare Conference, ahead of a broader trading and corporate update expected in February 2026.

From a market perspective, the outlook remains constrained by weak financial fundamentals, including substantial losses, negative equity and continued cash burn. Technical indicators are also negative, with the share price trading below key moving averages and a bearish MACD signal. While recent corporate progress and oversold technical conditions offer some support, these factors do not fully offset the prevailing financial and trend-related risks.

More about Renalytix

Renalytix is an artificial intelligence-enabled in vitro diagnostics company focused on improving the clinical management of chronic kidney disease. Its flagship product, kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test for early-stage risk assessment in diabetic kidney disease. The company targets large physician groups and health systems across the United States, where kidneyintelX.dkd is commercially available and supported by real-world performance data, inclusion in international CKD guidelines, and full Medicare reimbursement of $950 per reportable result.

Sintana Energy (LSE:SEI) has issued further clarification to address additional disclosure requests from the TSX Venture Exchange under Multilateral Instrument 61-101, relating to its acquisition of Challenger Energy Group via a scheme of arrangement that became effective on 16 December 2025.

The company reiterated that the transaction was conducted on an arm’s-length basis and qualified for exemptions from MI 61-101 requirements for a formal valuation and minority shareholder approval. Sintana explained that Challenger was not a related party, while the involvement of chief executive Robert Bose — a related party holding less than 10% of the shares in each company — remained below the 25% market capitalisation threshold that would otherwise have triggered additional protections.

As part of the disclosure, Sintana outlined Bose’s shareholdings before and after the transaction, confirming that he formally declared his interest and abstained from the board’s decision-making process. The company also noted that an independent special committee oversaw the transaction, obtaining an external valuation and fairness opinion before unanimously recommending the acquisition. These steps were highlighted as evidence of robust governance standards and measures designed to safeguard minority shareholders, while ensuring full regulatory compliance in connection with the Challenger deal.

More about Sintana Energy

Sintana Energy Inc. is a Canadian oil and gas company focused on the acquisition, exploration, potential development and monetisation of a diversified portfolio of high-impact hydrocarbon assets in emerging frontier regions. Its portfolio includes interests in eight licences across Namibia and Uruguay, a pending indirect interest in a licence offshore Angola, and legacy assets in Colombia and The Bahamas, providing exposure to multiple basins, operators, regulatory frameworks and geopolitical environments.

Nativo Resources (LSE:NTVO) has announced encouraging early results from its surface sampling and trenching programme at the Bonanza area within the Tesoro Concession in Peru. The findings confirm gold grades consistent with economic mining and support historical data previously reported by former operator St Elias Mines.

Sampling around the existing Bonanza workings delivered high-grade gold values of up to 19.5 g/t, with average grades of roughly 10 g/t from narrow mesothermal veins. Structural work has also identified three main shear-zone-controlled vein systems extending for up to 1 km, which the company believes are favourable for establishing continuous and sustainable production.

Alongside these exploration results, Nativo has completed underground rehabilitation and preparatory works, providing a foundation for detailed mine planning. Management intends to move toward a near-term restart of mining at Bonanza, while also advancing planning at Morrocota and gradually expanding gold exploration across the wider Tesoro Concession. Discussions with mining contractors are ongoing, and further underground sampling and geological modelling programmes are underway.

From a market perspective, the company’s outlook is constrained by very weak financial fundamentals, including ongoing losses, negative equity, high leverage relative to assets and continued cash burn. Technical indicators offer limited support following a sharp short-term rebound, but stretched momentum and trading below the 200-day moving average temper the signal. Valuation metrics remain unfavourable due to negative earnings and the absence of dividend support.

More about Nativo Resources Plc

Nativo Resources Plc is a Peru-focused gold mining company targeting primary gold production, ore processing and the recovery of gold from tailings. The group has acquired or secured options over several gold projects in Peru and is currently prioritising the development and scale-up of operations at the Tesoro Gold Concession, centred on the Bonanza and Morrocota mines. The company also plans to allocate a portion of future free cash flow and capital raises into Bitcoin as a long-term treasury reserve asset.